COMPASS Results For Clinical Practice Opinion of the Expert Council of November 22, 2017

1. Eikelboom J. W., Connolly S.J., Bosch J. et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377 (14):1319-1330.

2. Anand S., Bosch J., Eikelboom J. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Published online November 10, 2017 http://dx.doi.org/10.1016/S0140-6736 (17) 32409-1.

3. Connolly S., Eikelboom J., Bosch J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. Published Online November 10, 2017 http://dx.doi.org/10.1016/S0140-6736 (17) 32458-3

4. World Health Organization. Cardiovascular Diseases FactSheet. http://www.who.int/mediacentre/factsheets/fs317/en/.Accessed August 2017

5. Hiramoto J. S., Katz R., Weisman S. et al. Gender-specific risk factors for peripheral artery disease in a voluntary screening population. J Am Heart Assoc 2014;3 (2):e000651.

6. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003;

7. Aboyans V. Ricco J-B., Bartelink M-L. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal (2017) 00, 1-60.